Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for... see more

Recent & Breaking News (NDAQ:CNSP)

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

PR Newswire June 29, 2021

WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

GlobeNewswire June 28, 2021

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

PR Newswire June 17, 2021

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

PR Newswire May 19, 2021

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook

PR Newswire May 14, 2021

CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit

PR Newswire May 11, 2021

CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

PR Newswire March 15, 2021

CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

PR Newswire March 4, 2021

CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021

PR Newswire February 25, 2021

WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

GlobeNewswire February 24, 2021

WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

GlobeNewswire February 18, 2021

InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco

GlobeNewswire January 13, 2021

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

PR Newswire January 7, 2021

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

GlobeNewswire December 28, 2020

CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering

PR Newswire December 23, 2020

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

PR Newswire December 17, 2020

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

PR Newswire December 17, 2020

InvestorBrandNetwork Announces 'Want Money Got Money' Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco

GlobeNewswire December 16, 2020

CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

GlobeNewswire November 24, 2020

CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting

PR Newswire November 19, 2020